Stephen L. George, PhD


email this

Professor of Biostatistics and Bioinformatics
Biostatistics & Bioinformatics
2424 Erwin Road Ste 1102
11082 Hock Plaza
Durham, NC 27705
Office Telephone:
(919) 681-5003
  • PhD, Southern Methodist University, 1969
Representative Publications:
  • Baer, MR; George, SL; Sanford, BL; Mrózek, K; Kolitz, JE; Moore, JO; Stone, RM; Powell, BL; Caligiuri, MA; Bloomfield, CD; Larson, RA; Cancer and Leukemia Group B. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia. 2011;25:800-807.  Abstract
  • Buyse, M; Squifflet, P; Lange, BJ; Alonzo, TA; Larson, RA; Kolitz, JE; George, SL; Bloomfield, CD; Castaigne, S; Chevret, S; Blaise, D; Maraninchi, D; Lucchesi, KJ; Burzykowski, T. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 2011;117:7007-7013.  Abstract
  • Michiels, S; Potthoff, RF; George, SL. Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint. Statistics in Medicine. 2011;30:1502-1518.  Abstract
  • Sohn, I; Owzar, K; Lim, J; George, SL; Mackey Cushman, S; Jung, SH. Multiple testing for gene sets from microarray experiments. BMC Bioinformatics. 2011;12:209.  Abstract
  • Kolitz, JE; George, SL; Marcucci, G; Vij, R; Powell, BL; Allen, SL; DeAngelo, DJ; Shea, TC; Stock, W; Baer, MR; Hars, V; Maharry, K; Hoke, E; Vardiman, JW; Bloomfield, CD; Larson, RA; Cancer and Leukemia Group B. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010;116:1413-1421.  Abstract
  • Sargent, DJ; George, SL. Clinical trials data collection: when less is more. Journal of Clinical Oncology. 2010;28:5019-5021.  Abstract
  • Shterev, ID; Jung, SH; George, SL; Owzar, K. permGPU: Using graphics processing units in RNA microarray association studies. BMC Bioinformatics. 2010;11:329.  Abstract
  • Sohn, I; Owzar, K; George, SL; Kim, S; Jung, SH. Robust test method for time-course microarray experiments. BMC Bioinformatics. 2010;11:391.  Abstract
  • Jung, SH; George, SL. Between-arm comparisons in randomized Phase II trials. Journal of Biopharmaceutical Statistics. 2009;19:456-468.  Abstract
  • Jung, SH; Sohn, I; George, SL; Feng, L; Leppert, PC. Sample size calculation for microarray experiments with blocked one-way design. BMC Bioinformatics. 2009;10:164.  Abstract
  • Potthoff, RF; George, SL. Flexible Phase I Clinical Trials: Allowing for Nonbinary Toxicity Response and Removal of Other Common Limitations. Statistics in Biopharmaceutical Research. 2009;1:213-228.  Abstract
  • Sohn, I; Owzar, K; George, SL; Kim, S; Jung, SH. A permutation-based multiple testing method for time-course microarray experiments. BMC Bioinformatics. 2009;10:336.  Abstract
  • Baer, MR; George, SL; Caligiuri, MA; Sanford, BL; Bothun, SM; Mrózek, K; Kolitz, JE; Powell, BL; Moore, JO; Stone, RM; Anastasi, J; Bloomfield, CD; Larson, RA. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. Journal of Clinical Oncology. 2008;26:4934-4939.  Abstract
  • Demark-Wahnefried, W; George, SL; Switzer, BR; Snyder, DC; Madden, JF; Polascik, TJ; Ruffin, MT; Vollmer, RT. Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. Clinical Trials. 2008;5:262-272.  Abstract
  • Demark-Wahnefried, W; Polascik, TJ; George, SL; Switzer, BR; Madden, JF; Ruffin, MT; Snyder, DC; Owzar, K; Hars, V; Albala, DM; Walther, PJ; Robertson, CN; Moul, JW; Dunn, BK; Brenner, D; Minasian, L; Stella, P; Vollmer, RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiology, Biomarkers and Prevention. 2008;17:3577-3587.  Abstract
  • George, SL. Statistical issues in translational cancer research. Clinical Cancer Research. 2008;14:5954-5958.  Abstract
  • Green, MR; George, SL; Schilsky, RL; Cancer and Leukemia Group B. Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. Seminars in Oncology. 2008;35:470-483.  Abstract
  • Owzar, K; Barry, WT; Jung, SH; Sohn, I; George, SL. Statistical challenges in preprocessing in microarray experiments in cancer. Clinical Cancer Research. 2008;14:5959-5966.  Abstract
  • Freidlin, B; Korn, EL; George, SL; Gray, R. Randomized clinical trial design for assessing noninferiority when superiority is expected. Journal of Clinical Oncology. 2007;25:5019-5023.  Abstract
  • George, SL. Response rate as an endpoint in clinical trials. Journal of National Cancer Institute. 2007;99:98-99.  Abstract
  • Dilts, DM; Sandler, AB; Baker, M; Cheng, SK; George, SL; Karas, KS; McGuire, S; Menon, GS; Reusch, J; Sawyer, D; Scoggins, M; Wu, A; Zhou, K; Schilsky, RL; Case of Cancer and Leukemia Group B. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. Journal of Clinical Oncology. 2006;24:4553-4557.  Abstract
  • Jung, SH; Owzar, K; George, SL; Lee, T. P-value calculation for multistage phase II cancer clinical trials. Journal of Biopharmaceutical Statistics. 2006;16:765-775.  Abstract